New Oral Androgen Receptor Pathway Agents Are Changing the Way Prostate Cancer Is TreatedJanuary 18th 2013
The treatment of late-stage prostate cancer is shifting; with the approval of two new oral agents there are now more options for men with metastatic prostate cancer then just two years ago.
A United Front: Chesapeake Urology Associates Puts Its Singular Spin on Integrative CareJanuary 17th 2013
When the founding partners of Chesapeake Urology Associates (CUA) in Maryland decided to merge their practices, Sanford J. Siegel, MD, CUA's president and CEO, drew inspiration from another consolidation process.
Multidisciplinary Prostate Cancer Care at Duke Cancer Institute: An Interview With Judd W. Moul, MDJanuary 16th 2013
Judd W. Moul, MD, from the Duke Cancer Institute, comments on practice trends in urologic cancer care and the advantages and disadvantages of his institution's multidisciplinary prostate cancer clinic.
The USPSTF Prostate Cancer Screening Recommendations: Urologists Discuss Its Message and Impact on Their PracticesDecember 12th 2012
A panel of experts provides their thoughts on the USPSTF PSA screening recommendations, and how this widely publicized health message has impacted their urology practices.